News
LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced positive new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson's disease and adrenomyeloneuropathy (AMN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback